An Engrossing History of Azidothymidine
Azidothymidine (AZT) was the first breakthrough drug developed for the treatment of acquired immunodeficiency syndrome (AIDS). It took AZT only 25 months from the first successful laboratory activity against human immunodeficiency virus (HIV) to its approval by the FDA. Similar interesting facts and disputes have persistently been associated with AZT starting from its very first synthesis to the development and approval as drug. This review briefly collates the exciting history of AZT and, as the different stages involved in the discovery and the development of this drug molecule gets recapitulated here, could well serve as a mnemonic for the area of drug discovery and development in general..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Immunology, endocrine & metabolic agents in medicinal chemistry - 15(2015), 2, Seite 168-175 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
K. Sharma, Vivek [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1986721086 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC1986721086 | ||
| 003 | DE-627 | ||
| 005 | 20230518124703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170131s2015 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a fidpha_zeitschriften_20170130.pp |
| 035 | |a (DE-627)OLC1986721086 | ||
| 035 | |a (DE-599)GBVOLC1986721086 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a K. Sharma, Vivek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a An Engrossing History of Azidothymidine |
| 264 | 1 | |c 2015 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Azidothymidine (AZT) was the first breakthrough drug developed for the treatment of acquired immunodeficiency syndrome (AIDS). It took AZT only 25 months from the first successful laboratory activity against human immunodeficiency virus (HIV) to its approval by the FDA. Similar interesting facts and disputes have persistently been associated with AZT starting from its very first synthesis to the development and approval as drug. This review briefly collates the exciting history of AZT and, as the different stages involved in the discovery and the development of this drug molecule gets recapitulated here, could well serve as a mnemonic for the area of drug discovery and development in general. | ||
| 700 | 1 | |a K. Sharma, Raman |e verfasserin |4 aut | |
| 700 | 1 | |a K. Singh, Pramod |e verfasserin |4 aut | |
| 700 | 1 | |a K. Singh, Sunil |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunology, endocrine & metabolic agents in medicinal chemistry |d San Francisco, Calif. : Bentham Science Publ., 2006 |g 15(2015), 2, Seite 168-175 |w (DE-627)507526643 |w (DE-600)2221719-8 |w (DE-576)435514261 |x 1871-5222 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2015 |g number:2 |g pages:168-175 |
| 856 | 4 | 0 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5222&volume=15&issue=2&spage=168 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 15 |j 2015 |e 2 |h 168-175 | ||